1. Home
  2. PASG vs BRNS Comparison

PASG vs BRNS Comparison

Compare PASG & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PASG
  • BRNS
  • Stock Information
  • Founded
  • PASG 2017
  • BRNS 2016
  • Country
  • PASG United States
  • BRNS United Kingdom
  • Employees
  • PASG N/A
  • BRNS N/A
  • Industry
  • PASG Biotechnology: Pharmaceutical Preparations
  • BRNS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PASG Health Care
  • BRNS Health Care
  • Exchange
  • PASG Nasdaq
  • BRNS Nasdaq
  • Market Cap
  • PASG 31.1M
  • BRNS N/A
  • IPO Year
  • PASG 2020
  • BRNS 2021
  • Fundamental
  • Price
  • PASG $0.36
  • BRNS $0.76
  • Analyst Decision
  • PASG Strong Buy
  • BRNS Strong Buy
  • Analyst Count
  • PASG 3
  • BRNS 2
  • Target Price
  • PASG $7.67
  • BRNS $3.00
  • AVG Volume (30 Days)
  • PASG 160.6K
  • BRNS 15.1K
  • Earning Date
  • PASG 05-13-2025
  • BRNS 03-20-2025
  • Dividend Yield
  • PASG N/A
  • BRNS N/A
  • EPS Growth
  • PASG N/A
  • BRNS N/A
  • EPS
  • PASG N/A
  • BRNS N/A
  • Revenue
  • PASG N/A
  • BRNS $14,969,000.00
  • Revenue This Year
  • PASG N/A
  • BRNS N/A
  • Revenue Next Year
  • PASG N/A
  • BRNS N/A
  • P/E Ratio
  • PASG N/A
  • BRNS N/A
  • Revenue Growth
  • PASG N/A
  • BRNS 1766.46
  • 52 Week Low
  • PASG $0.33
  • BRNS $0.76
  • 52 Week High
  • PASG $1.64
  • BRNS $4.16
  • Technical
  • Relative Strength Index (RSI)
  • PASG 34.96
  • BRNS 28.76
  • Support Level
  • PASG $0.33
  • BRNS $1.01
  • Resistance Level
  • PASG $0.54
  • BRNS $1.06
  • Average True Range (ATR)
  • PASG 0.05
  • BRNS 0.07
  • MACD
  • PASG -0.00
  • BRNS -0.03
  • Stochastic Oscillator
  • PASG 14.20
  • BRNS 0.00

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Share on Social Networks: